DRUG/DEVICE

Treprostinil inhalation powder

ROUTE OF ADMINISTRATION

Inhaled

THERAPEUTIC PLATFORM

Tyvaso®

CLINICAL TRIAL

TERRITORY

Worldwide

COMMERCIAL PRODUCT

www.tyvaso.com

STATUS

NDA review underway, with FDA action anticipated October 2021

Tyvaso DPI is an investigational combination product that is not approved for any use in any country, and the Tyvaso DPI tradename is pending FDA review.